Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G. Rüschoff J, et al. Among authors: portier b. Virchows Arch. 2022 Nov;481(5):685-694. doi: 10.1007/s00428-022-03378-5. Epub 2022 Aug 16. Virchows Arch. 2022. PMID: 35970977 Free PMC article.
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC. Donaldson AR, et al. Among authors: portier bp. Cancer. 2017 Jun 15;123(12):2230-2239. doi: 10.1002/cncr.30592. Epub 2017 Feb 13. Cancer. 2017. PMID: 28192599 Free article.
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. Fiskus W, et al. Among authors: portier bp. Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22. Mol Cancer Ther. 2014. PMID: 25053825 Free PMC article.
Immunohistochemical Validation of Rare Tissues and Antigens With Low Frequency of Occurrence: Recommendations From The Anatomic Pathology Patient Interest Association (APPIA).
Lott RL, Riccelli PV, Sheppard EA, Wharton KA Jr, Walk EE, Kennedy G, Portier B. Lott RL, et al. Among authors: portier b. Appl Immunohistochem Mol Morphol. 2021 May-Jun 01;29(5):327-334. doi: 10.1097/PAI.0000000000000821. Appl Immunohistochem Mol Morphol. 2021. PMID: 32324630 Free PMC article.
43 results